656 ELI-002 immunotherapy induces broad polyfunctional T cell responses in subjects with high relapse risk KRAS mutated pancreatic ductal adenocarcinoma and colorectal cancer Article Swipe

PDF

James Perry , Lochana M. Seenappa , Haley VanWyk , Amy Tavares , Esther Welkowsky , Christopher M. Haqq , Peter C. DeMuth , Lisa K. McNeil ·

YOU? · · 2023 · Open Access · · DOI: https://doi.org/10.1136/jitc-2023-sitc2023.0656

Background Successful advancement of vaccine strategies for the treatment of solid tumors has been limited due to the limitations of vaccine delivery platforms and inadequate immune responses. ELI-002 immunotherapy uses Amphiphile (Amph) lymph node targeting to improve the potency of vaccination. Amph-modification promotes lipid-mediated binding to albumin resulting in delivery of antigen/adjuvant to lymph nodes where uptake by antigen-presenting cells leads to effective T cell activation. Kirsten rat sarcoma (KRAS) is mutated in one-quarter of human solid tumors, including approximately 90% of pancreatic ductal adenocarcinoma (PDAC) and 50% of colorectal cancer (CRC), making it an attractive target for lymph node-targeted immunotherapy using the Amph platform. ELI-002 2P was well tolerated, and 77% of patients exhibited biomarker response including 32% who exhibited circulating tumor DNA (ctDNA) clearance. Methods ELI-002–001 is a first-in-human Phase 1 trial of ELI-002 2P immunotherapy as adjuvant treatment for subjects with high relapse-risk mutant KRAS (mKRAS) PDAC and CRC. ELI-002 2P consists of 2 Amph-modified mKRAS peptide antigens, Amph-G12D and Amph-G12R (Amph-Peptides 2P), and a Amph-modified immune-stimulatory oligonucleotide adjuvant (Amph-CpG-7909). 25 subjects were randomized to receive ELI-002 2P at 1.4 mg of Amph-Peptides 2P and Amph-CpG-7909 at 5 dose levels; 0.1, 0.5, 2.5, 5, and 10 mg. Peripheral blood was collected longitudinally to assess specificity, polyfunctionality, and phenotype of mKRAS-specific T cells. Results 87% of evaluable subjects (20/23) induced mKRAS-specific T-cells post-vaccination as assessed by direct ex vivo Fluorospot and/or ICS assays with an average 56-fold increase from baseline. Further, a balanced CD4⁺ and CD8⁺ T cell response was observed in 50% of subjects and a majority were central and effector memory T cells. Evaluation of the breadth of responses to 7 different KRAS mutations revealed broad cross-reactivity to KRAS mutants including non-immunizing epitopes and low responses to WT. A high frequency of polyfunctional cells secreting IFNγ, TNFα, IL-2, and/or Granzyme B was observed. Additional phenotypic and functional analysis of mKRAS-specific T cells is ongoing. Conclusions ELI-002 induces robust and broadly reactive mKRAS-specific T cell responses in most subjects (87%) at high risk for relapse. This off-the-shelf lymph node-targeted vaccine has many advantages including high immunogenicity yielding balanced CD4⁺ and CD8⁺ T cell responses targeting vaccine antigens that are critical for tumor survival. A Phase 1/2 clinical trial investigating a new 7 peptide formulation, ELI-002 7P (G12D, R, V, A, C, S, G13D; NCT NCT05726864), is currently in progress. Trial Registration NCT04853017 Ethics Approval The study was approved by the local institutional review board at each study site and the US FDA. All patients provided written and informed consent.

Related Topics

Concepts

KRAS Medicine Adjuvant Immunotherapy Cancer research Lymph node Antigen Pancreatic cancer Immune system Colorectal cancer Adenocarcinoma Cancer Oncology Internal medicine Immunology

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.1136/jitc-2023-sitc2023.0656
PDF: https://jitc.bmj.com/content/jitc/11/Suppl_1/A748.full.pdf
OA Status: hybrid
Cited By: 1
Related Works: 10
OpenAlex ID: https://openalex.org/W4388081964

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4388081964

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1136/jitc-2023-sitc2023.0656

Digital Object Identifier
Title: 656 ELI-002 immunotherapy induces broad polyfunctional T cell responses in subjects with high relapse risk KRAS mutated pancreatic ductal adenocarcinoma and colorectal cancer

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2023

Year of publication
Publication date: 2023-10-31

Full publication date if available
Authors: James Perry, Lochana M. Seenappa, Haley VanWyk, Amy Tavares, Esther Welkowsky, Christopher M. Haqq, Peter C. DeMuth, Lisa K. McNeil

List of authors in order
Landing page: https://doi.org/10.1136/jitc-2023-sitc2023.0656

Publisher landing page
PDF URL: https://jitc.bmj.com/content/jitc/11/Suppl_1/A748.full.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: hybrid

Open access status per OpenAlex
OA URL: https://jitc.bmj.com/content/jitc/11/Suppl_1/A748.full.pdf

Direct OA link when available
Concepts: KRAS, Medicine, Adjuvant, Immunotherapy, Cancer research, Lymph node, Antigen, Pancreatic cancer, Immune system, Colorectal cancer, Adenocarcinoma, Cancer, Oncology, Internal medicine, Immunology

Top concepts (fields/topics) attached by OpenAlex
Cited by: 1

Total citation count in OpenAlex
Citations by year (recent): 2024: 1

Per-year citation counts (last 5 years)
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4388081964
doi	https://doi.org/10.1136/jitc-2023-sitc2023.0656
ids.doi	https://doi.org/10.1136/jitc-2023-sitc2023.0656
ids.openalex	https://openalex.org/W4388081964
fwci	0.19393687
type	article
title	656 ELI-002 immunotherapy induces broad polyfunctional T cell responses in subjects with high relapse risk KRAS mutated pancreatic ductal adenocarcinoma and colorectal cancer
biblio.issue
biblio.volume
biblio.last_page	A748
biblio.first_page	A748
topics[0].id	https://openalex.org/T10580
topics[0].field.id	https://openalex.org/fields/24
topics[0].field.display_name	Immunology and Microbiology
topics[0].score	0.9995999932289124
topics[0].domain.id	https://openalex.org/domains/1
topics[0].domain.display_name	Life Sciences
topics[0].subfield.id	https://openalex.org/subfields/2403
topics[0].subfield.display_name	Immunology
topics[0].display_name	Immunotherapy and Immune Responses
topics[1].id	https://openalex.org/T11491
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9983000159263611
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2730
topics[1].subfield.display_name	Oncology
topics[1].display_name	CAR-T cell therapy research
topics[2].id	https://openalex.org/T10158
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9955000281333923
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2730
topics[2].subfield.display_name	Oncology
topics[2].display_name	Cancer Immunotherapy and Biomarkers
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2781187634
concepts[0].level	4
concepts[0].score	0.6321315765380859
concepts[0].wikidata	https://www.wikidata.org/wiki/Q20969980
concepts[0].display_name	KRAS
concepts[1].id	https://openalex.org/C71924100
concepts[1].level	0
concepts[1].score	0.629179835319519
concepts[1].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[1].display_name	Medicine
concepts[2].id	https://openalex.org/C2777863537
concepts[2].level	2
concepts[2].score	0.5896877646446228
concepts[2].wikidata	https://www.wikidata.org/wiki/Q357896
concepts[2].display_name	Adjuvant
concepts[3].id	https://openalex.org/C2777701055
concepts[3].level	3
concepts[3].score	0.5705026388168335
concepts[3].wikidata	https://www.wikidata.org/wiki/Q1427096
concepts[3].display_name	Immunotherapy
concepts[4].id	https://openalex.org/C502942594
concepts[4].level	1
concepts[4].score	0.5502023696899414
concepts[4].wikidata	https://www.wikidata.org/wiki/Q3421914
concepts[4].display_name	Cancer research
concepts[5].id	https://openalex.org/C2780849966
concepts[5].level	2
concepts[5].score	0.544163703918457
concepts[5].wikidata	https://www.wikidata.org/wiki/Q170758
concepts[5].display_name	Lymph node
concepts[6].id	https://openalex.org/C147483822
concepts[6].level	2
concepts[6].score	0.4562673270702362
concepts[6].wikidata	https://www.wikidata.org/wiki/Q103537
concepts[6].display_name	Antigen
concepts[7].id	https://openalex.org/C2780210213
concepts[7].level	3
concepts[7].score	0.4295910894870758
concepts[7].wikidata	https://www.wikidata.org/wiki/Q212961
concepts[7].display_name	Pancreatic cancer
concepts[8].id	https://openalex.org/C8891405
concepts[8].level	2
concepts[8].score	0.42707398533821106
concepts[8].wikidata	https://www.wikidata.org/wiki/Q1059
concepts[8].display_name	Immune system
concepts[9].id	https://openalex.org/C526805850
concepts[9].level	3
concepts[9].score	0.4270550608634949
concepts[9].wikidata	https://www.wikidata.org/wiki/Q188874
concepts[9].display_name	Colorectal cancer
concepts[10].id	https://openalex.org/C2781182431
concepts[10].level	3
concepts[10].score	0.41709062457084656
concepts[10].wikidata	https://www.wikidata.org/wiki/Q356033
concepts[10].display_name	Adenocarcinoma
concepts[11].id	https://openalex.org/C121608353
concepts[11].level	2
concepts[11].score	0.41660910844802856
concepts[11].wikidata	https://www.wikidata.org/wiki/Q12078
concepts[11].display_name	Cancer
concepts[12].id	https://openalex.org/C143998085
concepts[12].level	1
concepts[12].score	0.39929455518722534
concepts[12].wikidata	https://www.wikidata.org/wiki/Q162555
concepts[12].display_name	Oncology
concepts[13].id	https://openalex.org/C126322002
concepts[13].level	1
concepts[13].score	0.3941449522972107
concepts[13].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[13].display_name	Internal medicine
concepts[14].id	https://openalex.org/C203014093
concepts[14].level	1
concepts[14].score	0.3355989456176758
concepts[14].wikidata	https://www.wikidata.org/wiki/Q101929
concepts[14].display_name	Immunology
keywords[0].id	https://openalex.org/keywords/kras
keywords[0].score	0.6321315765380859
keywords[0].display_name	KRAS
keywords[1].id	https://openalex.org/keywords/medicine
keywords[1].score	0.629179835319519
keywords[1].display_name	Medicine
keywords[2].id	https://openalex.org/keywords/adjuvant
keywords[2].score	0.5896877646446228
keywords[2].display_name	Adjuvant
keywords[3].id	https://openalex.org/keywords/immunotherapy
keywords[3].score	0.5705026388168335
keywords[3].display_name	Immunotherapy
keywords[4].id	https://openalex.org/keywords/cancer-research
keywords[4].score	0.5502023696899414
keywords[4].display_name	Cancer research
keywords[5].id	https://openalex.org/keywords/lymph-node
keywords[5].score	0.544163703918457
keywords[5].display_name	Lymph node
keywords[6].id	https://openalex.org/keywords/antigen
keywords[6].score	0.4562673270702362
keywords[6].display_name	Antigen
keywords[7].id	https://openalex.org/keywords/pancreatic-cancer
keywords[7].score	0.4295910894870758
keywords[7].display_name	Pancreatic cancer
keywords[8].id	https://openalex.org/keywords/immune-system
keywords[8].score	0.42707398533821106
keywords[8].display_name	Immune system
keywords[9].id	https://openalex.org/keywords/colorectal-cancer
keywords[9].score	0.4270550608634949
keywords[9].display_name	Colorectal cancer
keywords[10].id	https://openalex.org/keywords/adenocarcinoma
keywords[10].score	0.41709062457084656
keywords[10].display_name	Adenocarcinoma
keywords[11].id	https://openalex.org/keywords/cancer
keywords[11].score	0.41660910844802856
keywords[11].display_name	Cancer
keywords[12].id	https://openalex.org/keywords/oncology
keywords[12].score	0.39929455518722534
keywords[12].display_name	Oncology
keywords[13].id	https://openalex.org/keywords/internal-medicine
keywords[13].score	0.3941449522972107
keywords[13].display_name	Internal medicine
keywords[14].id	https://openalex.org/keywords/immunology
keywords[14].score	0.3355989456176758
keywords[14].display_name	Immunology
language	en
locations[0].id	doi:10.1136/jitc-2023-sitc2023.0656
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S4363604233
locations[0].source.issn
locations[0].source.type	journal
locations[0].source.is_oa	False
locations[0].source.issn_l
locations[0].source.is_core	True
locations[0].source.is_in_doaj	False
locations[0].source.display_name	Regular and Young Investigator Award Abstracts
locations[0].source.host_organization
locations[0].source.host_organization_name
locations[0].source.host_organization_lineage
locations[0].license	cc-by-nc
locations[0].pdf_url	https://jitc.bmj.com/content/jitc/11/Suppl_1/A748.full.pdf
locations[0].version	publishedVersion
locations[0].raw_type	proceedings-article
locations[0].license_id	https://openalex.org/licenses/cc-by-nc
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	Regular and Young Investigator Award Abstracts
locations[0].landing_page_url	https://doi.org/10.1136/jitc-2023-sitc2023.0656
locations[1].id	pmh:oai:doaj.org/article:1c71d7ed4fa54b02b40337420eac3bf9
locations[1].is_oa	False
locations[1].source.id	https://openalex.org/S4306401280
locations[1].source.issn
locations[1].source.type	repository
locations[1].source.is_oa	False
locations[1].source.issn_l
locations[1].source.is_core	False
locations[1].source.is_in_doaj	False
locations[1].source.display_name	DOAJ (DOAJ: Directory of Open Access Journals)
locations[1].source.host_organization
locations[1].source.host_organization_name
locations[1].source.host_organization_lineage
locations[1].license
locations[1].pdf_url
locations[1].version	submittedVersion
locations[1].raw_type	article
locations[1].license_id
locations[1].is_accepted	False
locations[1].is_published	False
locations[1].raw_source_name	Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
locations[1].landing_page_url	https://doaj.org/article/1c71d7ed4fa54b02b40337420eac3bf9
indexed_in	crossref, doaj
authorships[0].author.id	https://openalex.org/A5102708924
authorships[0].author.orcid	https://orcid.org/0000-0003-0698-6037
authorships[0].author.display_name	James Perry
authorships[0].affiliations[0].raw_affiliation_string	Elicio Therapeutics Inc., Boston, MA, USA
authorships[0].author_position	first
authorships[0].raw_author_name	James R Perry
authorships[0].is_corresponding	False
authorships[0].raw_affiliation_strings	Elicio Therapeutics Inc., Boston, MA, USA
authorships[1].author.id	https://openalex.org/A5082816021
authorships[1].author.orcid	https://orcid.org/0000-0003-0543-5495
authorships[1].author.display_name	Lochana M. Seenappa
authorships[1].affiliations[0].raw_affiliation_string	Elicio Therapeutics Inc., Boston, MA, USA
authorships[1].author_position	middle
authorships[1].raw_author_name	Lochana M Seenappa
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	Elicio Therapeutics Inc., Boston, MA, USA
authorships[2].author.id
authorships[2].author.orcid
authorships[2].author.display_name
authorships[2].affiliations[0].raw_affiliation_string	Elicio Therapeutics Inc., Boston, MA, USA
authorships[2].author_position	middle
authorships[2].raw_author_name	Haley VanWyk
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	Elicio Therapeutics Inc., Boston, MA, USA
authorships[3].author.id	https://openalex.org/A5108915431
authorships[3].author.orcid
authorships[3].author.display_name	Amy Tavares
authorships[3].affiliations[0].raw_affiliation_string	Elicio Therapeutics, Fairhaven, MA, USA
authorships[3].author_position	middle
authorships[3].raw_author_name	Amy M Tavares
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	Elicio Therapeutics, Fairhaven, MA, USA
authorships[4].author.id	https://openalex.org/A5017690480
authorships[4].author.orcid
authorships[4].author.display_name	Esther Welkowsky
authorships[4].affiliations[0].raw_affiliation_string	Elicio Therapeutics Inc., Boston, MA, USA
authorships[4].author_position	middle
authorships[4].raw_author_name	Esther Welkowsky
authorships[4].is_corresponding	False
authorships[4].raw_affiliation_strings	Elicio Therapeutics Inc., Boston, MA, USA
authorships[5].author.id	https://openalex.org/A5108460394
authorships[5].author.orcid
authorships[5].author.display_name	Christopher M. Haqq
authorships[5].affiliations[0].raw_affiliation_string	Elicio Therapeutics Inc., Boston, MA, USA
authorships[5].author_position	middle
authorships[5].raw_author_name	Christopher M Haqq
authorships[5].is_corresponding	False
authorships[5].raw_affiliation_strings	Elicio Therapeutics Inc., Boston, MA, USA
authorships[6].author.id	https://openalex.org/A5059987828
authorships[6].author.orcid	https://orcid.org/0000-0002-7044-7559
authorships[6].author.display_name	Peter C. DeMuth
authorships[6].affiliations[0].raw_affiliation_string	Elicio Therapeutics Inc., Boston, MA, USA
authorships[6].author_position	middle
authorships[6].raw_author_name	Peter C DeMuth
authorships[6].is_corresponding	False
authorships[6].raw_affiliation_strings	Elicio Therapeutics Inc., Boston, MA, USA
authorships[7].author.id	https://openalex.org/A5114046370
authorships[7].author.orcid
authorships[7].author.display_name	Lisa K. McNeil
authorships[7].affiliations[0].raw_affiliation_string	Elicio Therapeutics Inc., Boston, MA, USA
authorships[7].author_position	last
authorships[7].raw_author_name	Lisa K McNeil
authorships[7].is_corresponding	False
authorships[7].raw_affiliation_strings	Elicio Therapeutics Inc., Boston, MA, USA
has_content.pdf	True
has_content.grobid_xml	True
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://jitc.bmj.com/content/jitc/11/Suppl_1/A748.full.pdf
open_access.oa_status	hybrid
open_access.any_repository_has_fulltext	False
created_date	2023-11-01T00:00:00
display_name	656 ELI-002 immunotherapy induces broad polyfunctional T cell responses in subjects with high relapse risk KRAS mutated pancreatic ductal adenocarcinoma and colorectal cancer
has_fulltext	True
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10580
primary_topic.field.id	https://openalex.org/fields/24
primary_topic.field.display_name	Immunology and Microbiology
primary_topic.score	0.9995999932289124
primary_topic.domain.id	https://openalex.org/domains/1
primary_topic.domain.display_name	Life Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2403
primary_topic.subfield.display_name	Immunology
primary_topic.display_name	Immunotherapy and Immune Responses
related_works	https://openalex.org/W3030972949, https://openalex.org/W4283712951, https://openalex.org/W4229832877, https://openalex.org/W4306404900, https://openalex.org/W3111812619, https://openalex.org/W4248366929, https://openalex.org/W2590035663, https://openalex.org/W2914997899, https://openalex.org/W4229670017, https://openalex.org/W4226309907
cited_by_count	1
counts_by_year[0].year	2024
counts_by_year[0].cited_by_count	1
locations_count	2
best_oa_location.id	doi:10.1136/jitc-2023-sitc2023.0656
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S4363604233
best_oa_location.source.issn
best_oa_location.source.type	journal
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l
best_oa_location.source.is_core	True
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	Regular and Young Investigator Award Abstracts
best_oa_location.source.host_organization
best_oa_location.source.host_organization_name
best_oa_location.source.host_organization_lineage
best_oa_location.license	cc-by-nc
best_oa_location.pdf_url	https://jitc.bmj.com/content/jitc/11/Suppl_1/A748.full.pdf
best_oa_location.version	publishedVersion
best_oa_location.raw_type	proceedings-article
best_oa_location.license_id	https://openalex.org/licenses/cc-by-nc
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	Regular and Young Investigator Award Abstracts
best_oa_location.landing_page_url	https://doi.org/10.1136/jitc-2023-sitc2023.0656
primary_location.id	doi:10.1136/jitc-2023-sitc2023.0656
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S4363604233
primary_location.source.issn
primary_location.source.type	journal
primary_location.source.is_oa	False
primary_location.source.issn_l
primary_location.source.is_core	True
primary_location.source.is_in_doaj	False
primary_location.source.display_name	Regular and Young Investigator Award Abstracts
primary_location.source.host_organization
primary_location.source.host_organization_name
primary_location.source.host_organization_lineage
primary_location.license	cc-by-nc
primary_location.pdf_url	https://jitc.bmj.com/content/jitc/11/Suppl_1/A748.full.pdf
primary_location.version	publishedVersion
primary_location.raw_type	proceedings-article
primary_location.license_id	https://openalex.org/licenses/cc-by-nc
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	Regular and Young Investigator Award Abstracts
primary_location.landing_page_url	https://doi.org/10.1136/jitc-2023-sitc2023.0656
publication_date	2023-10-31
publication_year	2023
referenced_works_count	0
abstract_inverted_index.1	132
abstract_inverted_index.2	156
abstract_inverted_index.5	190
abstract_inverted_index.7	274, 374
abstract_inverted_index.A	292, 366
abstract_inverted_index.B	304
abstract_inverted_index.T	63, 213, 248, 265, 314, 326, 354
abstract_inverted_index.a	129, 167, 243, 258, 372
abstract_inverted_index.10	198
abstract_inverted_index.25	173
abstract_inverted_index.2P	106, 136, 153, 180, 186
abstract_inverted_index.5,	196
abstract_inverted_index.7P	378
abstract_inverted_index.A,	382
abstract_inverted_index.C,	383
abstract_inverted_index.R,	380
abstract_inverted_index.S,	384
abstract_inverted_index.US	413
abstract_inverted_index.V,	381
abstract_inverted_index.an	94, 236
abstract_inverted_index.as	138, 225
abstract_inverted_index.at	181, 189, 333, 407
abstract_inverted_index.by	57, 227, 401
abstract_inverted_index.ex	229
abstract_inverted_index.in	48, 72, 253, 329, 390
abstract_inverted_index.is	70, 128, 316, 388
abstract_inverted_index.it	93
abstract_inverted_index.mg	183
abstract_inverted_index.of	3, 9, 19, 39, 50, 74, 81, 88, 112, 134, 155, 184, 211, 217, 255, 268, 271, 295, 312
abstract_inverted_index.to	16, 35, 45, 52, 61, 177, 205, 273, 281, 290
abstract_inverted_index.1.4	182
abstract_inverted_index.1/2	368
abstract_inverted_index.32%	118
abstract_inverted_index.50%	87, 254
abstract_inverted_index.77%	111
abstract_inverted_index.87%	216
abstract_inverted_index.90%	80
abstract_inverted_index.All	415
abstract_inverted_index.DNA	123
abstract_inverted_index.ICS	233
abstract_inverted_index.NCT	386
abstract_inverted_index.The	397
abstract_inverted_index.WT.	291
abstract_inverted_index.and	23, 86, 110, 150, 162, 166, 187, 197, 209, 246, 257, 262, 287, 309, 322, 352, 411, 419
abstract_inverted_index.are	361
abstract_inverted_index.due	15
abstract_inverted_index.for	6, 97, 141, 336, 363
abstract_inverted_index.has	12, 343
abstract_inverted_index.low	288
abstract_inverted_index.mg.	199
abstract_inverted_index.new	373
abstract_inverted_index.rat	67
abstract_inverted_index.the	7, 17, 37, 102, 269, 402, 412
abstract_inverted_index.was	107, 202, 251, 305, 399
abstract_inverted_index.who	119
abstract_inverted_index.0.1,	193
abstract_inverted_index.0.5,	194
abstract_inverted_index.2.5,	195
abstract_inverted_index.2P),	165
abstract_inverted_index.Amph	103
abstract_inverted_index.CRC.	151
abstract_inverted_index.FDA.	414
abstract_inverted_index.KRAS	147, 276, 282
abstract_inverted_index.PDAC	149
abstract_inverted_index.This	338
abstract_inverted_index.been	13
abstract_inverted_index.cell	64, 249, 327, 355
abstract_inverted_index.dose	191
abstract_inverted_index.each	408
abstract_inverted_index.from	240
abstract_inverted_index.high	144, 293, 334, 347
abstract_inverted_index.many	344
abstract_inverted_index.most	330
abstract_inverted_index.node	33
abstract_inverted_index.risk	335
abstract_inverted_index.site	410
abstract_inverted_index.that	360
abstract_inverted_index.uses	29
abstract_inverted_index.vivo	230
abstract_inverted_index.well	108
abstract_inverted_index.were	175, 260
abstract_inverted_index.with	143, 235
abstract_inverted_index.(87%)	332
abstract_inverted_index.G13D;	385
abstract_inverted_index.IL-2,	301
abstract_inverted_index.Phase	131, 367
abstract_inverted_index.blood	201
abstract_inverted_index.board	406
abstract_inverted_index.broad	279
abstract_inverted_index.cells	59, 297, 315
abstract_inverted_index.human	75
abstract_inverted_index.leads	60
abstract_inverted_index.local	403
abstract_inverted_index.lymph	32, 53, 98, 340
abstract_inverted_index.mKRAS	158
abstract_inverted_index.nodes	54
abstract_inverted_index.solid	10, 76
abstract_inverted_index.study	398, 409
abstract_inverted_index.trial	133, 370
abstract_inverted_index.tumor	122, 364
abstract_inverted_index.using	101
abstract_inverted_index.where	55
abstract_inverted_index.(Amph)	31
abstract_inverted_index.(CRC),	91
abstract_inverted_index.(G12D,	379
abstract_inverted_index.(KRAS)	69
abstract_inverted_index.(PDAC)	85
abstract_inverted_index.IFNγ,	299
abstract_inverted_index.TNFα,	300
abstract_inverted_index.and/or	232, 302
abstract_inverted_index.assays	234
abstract_inverted_index.assess	206
abstract_inverted_index.cancer	90
abstract_inverted_index.cells.	214, 266
abstract_inverted_index.direct	228
abstract_inverted_index.ductal	83
abstract_inverted_index.immune	25
abstract_inverted_index.making	92
abstract_inverted_index.memory	264
abstract_inverted_index.mutant	146
abstract_inverted_index.review	405
abstract_inverted_index.robust	321
abstract_inverted_index.target	96
abstract_inverted_index.tumors	11
abstract_inverted_index.uptake	56
abstract_inverted_index.(20/23)	220
abstract_inverted_index.(ctDNA)	124
abstract_inverted_index.(mKRAS)	148
abstract_inverted_index.56-fold	238
abstract_inverted_index.ELI-002	27, 105, 135, 152, 179, 319, 377
abstract_inverted_index.Kirsten	66
abstract_inverted_index.T-cells	223
abstract_inverted_index.albumin	46
abstract_inverted_index.average	237
abstract_inverted_index.binding	44
abstract_inverted_index.breadth	270
abstract_inverted_index.broadly	323
abstract_inverted_index.central	261
abstract_inverted_index.improve	36
abstract_inverted_index.induced	221
abstract_inverted_index.induces	320
abstract_inverted_index.levels;	192
abstract_inverted_index.limited	14
abstract_inverted_index.mutants	283
abstract_inverted_index.mutated	71
abstract_inverted_index.peptide	159, 375
abstract_inverted_index.potency	38
abstract_inverted_index.receive	178
abstract_inverted_index.sarcoma	68
abstract_inverted_index.tumors,	77
abstract_inverted_index.vaccine	4, 20, 342, 358
abstract_inverted_index.written	418
abstract_inverted_index.Further,	242
abstract_inverted_index.Granzyme	303
abstract_inverted_index.adjuvant	139, 171
abstract_inverted_index.analysis	311
abstract_inverted_index.antigens	359
abstract_inverted_index.approved	400
abstract_inverted_index.assessed	226
abstract_inverted_index.balanced	244, 350
abstract_inverted_index.clinical	369
abstract_inverted_index.consent.	421
abstract_inverted_index.consists	154
abstract_inverted_index.critical	362
abstract_inverted_index.delivery	21, 49
abstract_inverted_index.effector	263
abstract_inverted_index.epitopes	286
abstract_inverted_index.increase	239
abstract_inverted_index.informed	420
abstract_inverted_index.majority	259
abstract_inverted_index.observed	252
abstract_inverted_index.ongoing.	317
abstract_inverted_index.patients	113, 416
abstract_inverted_index.promotes	42
abstract_inverted_index.provided	417
abstract_inverted_index.reactive	324
abstract_inverted_index.relapse.	337
abstract_inverted_index.response	116, 250
abstract_inverted_index.revealed	278
abstract_inverted_index.subjects	142, 174, 219, 256, 331
abstract_inverted_index.yielding	349
abstract_inverted_index.<h3>Trial	392
abstract_inverted_index.Amph-G12D	161
abstract_inverted_index.Amph-G12R	163
abstract_inverted_index.antigens,	160
abstract_inverted_index.baseline.	241
abstract_inverted_index.biomarker	115
abstract_inverted_index.collected	203
abstract_inverted_index.currently	389
abstract_inverted_index.different	275
abstract_inverted_index.effective	62
abstract_inverted_index.evaluable	218
abstract_inverted_index.exhibited	114, 120
abstract_inverted_index.frequency	294
abstract_inverted_index.including	78, 117, 284, 346
abstract_inverted_index.mutations	277
abstract_inverted_index.observed.	306
abstract_inverted_index.phenotype	210
abstract_inverted_index.platform.	104
abstract_inverted_index.platforms	22
abstract_inverted_index.progress.	391
abstract_inverted_index.responses	272, 289, 328, 356
abstract_inverted_index.resulting	47
abstract_inverted_index.secreting	298
abstract_inverted_index.survival.	365
abstract_inverted_index.targeting	34, 357
abstract_inverted_index.treatment	8, 140
abstract_inverted_index.<h3>Ethics	395
abstract_inverted_index.Additional	307
abstract_inverted_index.Amphiphile	30
abstract_inverted_index.Evaluation	267
abstract_inverted_index.Fluorospot	231
abstract_inverted_index.Peripheral	200
abstract_inverted_index.Successful	1
abstract_inverted_index.advantages	345
abstract_inverted_index.attractive	95
abstract_inverted_index.clearance.	125
abstract_inverted_index.colorectal	89
abstract_inverted_index.functional	310
abstract_inverted_index.inadequate	24
abstract_inverted_index.pancreatic	82
abstract_inverted_index.phenotypic	308
abstract_inverted_index.randomized	176
abstract_inverted_index.responses.	26
abstract_inverted_index.strategies	5
abstract_inverted_index.tolerated,	109
abstract_inverted_index.NCT04853017	394
abstract_inverted_index.activation.	65
abstract_inverted_index.advancement	2
abstract_inverted_index.circulating	121
abstract_inverted_index.limitations	18
abstract_inverted_index.one-quarter	73
abstract_inverted_index.formulation,	376
abstract_inverted_index.relapse-risk	145
abstract_inverted_index.specificity,	207
abstract_inverted_index.vaccination.	40
abstract_inverted_index.Amph-CpG-7909	188
abstract_inverted_index.Amph-Peptides	185
abstract_inverted_index.Amph-modified	157, 168
abstract_inverted_index.Approval</h3>	396
abstract_inverted_index.ELI-002–001	127
abstract_inverted_index.NCT05726864),	387
abstract_inverted_index.approximately	79
abstract_inverted_index.immunotherapy	28, 100, 137
abstract_inverted_index.institutional	404
abstract_inverted_index.investigating	371
abstract_inverted_index.node-targeted	99, 341
abstract_inverted_index.off-the-shelf	339
abstract_inverted_index.(Amph-Peptides	164
abstract_inverted_index.adenocarcinoma	84
abstract_inverted_index.first-in-human	130
abstract_inverted_index.immunogenicity	348
abstract_inverted_index.lipid-mediated	43
abstract_inverted_index.longitudinally	204
abstract_inverted_index.mKRAS-specific	212, 222, 313, 325
abstract_inverted_index.non-immunizing	285
abstract_inverted_index.polyfunctional	296
abstract_inverted_index.CD4<sup>+</sup>	245, 351
abstract_inverted_index.CD8<sup>+</sup>	247, 353
abstract_inverted_index.oligonucleotide	170
abstract_inverted_index.(Amph-CpG-7909).	172
abstract_inverted_index.<h3>Methods</h3>	126
abstract_inverted_index.<h3>Results</h3>	215
abstract_inverted_index.antigen/adjuvant	51
abstract_inverted_index.cross-reactivity	280
abstract_inverted_index.post-vaccination	224
abstract_inverted_index.Amph-modification	41
abstract_inverted_index.Registration</h3>	393
abstract_inverted_index.antigen-presenting	58
abstract_inverted_index.immune-stimulatory	169
abstract_inverted_index.polyfunctionality,	208
abstract_inverted_index.<h3>Background</h3>	0
abstract_inverted_index.<h3>Conclusions</h3>	318
cited_by_percentile_year.max	94
cited_by_percentile_year.min	90
countries_distinct_count	0
institutions_distinct_count	8
sustainable_development_goals[0].id	https://metadata.un.org/sdg/3
sustainable_development_goals[0].score	0.6700000166893005
sustainable_development_goals[0].display_name	Good health and well-being
citation_normalized_percentile.value	0.63380167
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False